IBsolvMIR® for regenerative celltherapies

IBsolvMIR® is developed to improve cell transplantation for treatment of patients receiving therapeutic celltherapy.

A major complication for the transplantation is IBMIR, an innate immunity reaction which kills approximately 50% the cells transplanted.

TikoMeds product is the most effective substance for elimination of the IBMIR effects. A Phase 2 study has been finalized, sponsored by the National Institutes of Health (US government) with $15M, in collaboration with Uppsala University, Karolinska Institute and Oslo University.

Follow-up studies are planned in Europe.

IBsolvMIR® has obtained Orphan Drug designation status in both EU and US.